2014 Speakers

2014 Speakers and Participants

  • Karen Akinsanya, PhD, Associate Vice President, Early Stage Assessment & Alliance Management Lead, Merck
  • Janelle Anderson, Managing Director, MRL Ventures Fund
  • Querida Anderson, Editor in Chief, BioPharm Insight
  • William D. “Chip” Baird, Chief Financial Officer, Amicus Therapeutics
  • Jane Baj, Director Corporate Communications, PTC Therapeutics, Inc.
  • Franklin M. Berger, CFA, FMB
  • Peter I. Bernstein, Partner, Scully, Scott, Murphy & Presser, P.C.
  • Laurence Blumberg, MD, Co-Founder, President & CEO, Syntimmune, Inc.
  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Jarrod Borkat, Head, External Collaborations and Biotech Hubs, MedImmune, LLC
  • Mohan Chellani, MBA, PhD, President, Progen LifeSciences
  • Eric B. Cheng, Senior Managing Director, Head of Healthcare Investment Banking, Maxim Group LLC
  • Jonathan Cohen, President & CEO, 20/20 GeneSystems Inc.
  • Mary S. Consalvi, Partner, Proskauer Rose LLP
  • Bruce R. Conway, PhD, Program Director, Robertson Therapeutic Development Fund, The Rockefeller University
  • Ellen B. Corenswet, Partner, Covington & Burling LLP
  • Benjamin R. Cowen, PhD, MBA, Vice President, Business Development, PDS Biotechnology
  • Pamela R. Demain, Executive Director, Corporate Licensing, Merck & Co., Inc.
  • George de Santis, Sanofi
  • Peter DiLaura, President & Chief Executive Officer, Second Genome, Inc.
  • Peter Donnelly, Director, Technology Licensing and Industry Relations, Stony Brook University
  • Harry Edelson, Edelson Technology Partners
  • Dan Farrell, Chairman & Chief Executive Officer, Privos Capital
  • Howard Fillit, MD, Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation
  • James Foley, PhD, Managing Director, Aqua Partners, LLC
  • Les Funtleyder, Director of Strategic Investments, OPKO Health, Healthcare Portfolio Manager, E Squared Asset Management
  • Michela Gallagher, PhD, Krieger Eisenhower Professor, Psychology & Neuroscience, Johns Hopkins School of Medicine; Founder and Chief Scientific Officer, Agenebio
  • Thomas Gallagher, Senior Vice President, Intellectual Property, Kadmon Corporation
  • Pia Maria Gargiulo, PhD, Former Managing Director of Companion Diagnostics, Precision for Medicine, Inc.
  • Robert H. Glassman, MD, Managing Director, Global Healthcare Investment Banking, Bank of America Merrill Lynch
  • Edwin H. Gordon, Head of Healthcare and Life Sciences Group, Ladenburg Thalman
  • Sherry Grisewood, CFA, Managing Director, Corporate Finance, Dawson James Securities, Inc.
  • Joseph V. Gulfo, MD, MBA, Author, Biopharm/Medtech CEO, Professor
  • Kimberly Ha, Senior Director, FTI Consulting
  • Magali Haas, MD, PhD, Founder and Chief Executive Officer, Orion Bionetworks
  • John Haley, PhD, Director, Developmental Therapeutics, Stony Brook University Cancer Center
  • Klaudyne Hong, PhD, Founder, Temasek Bioscience Partners
  • Ramy Ibrahim, MD, Clinical VIce President, Immuno-Oncology, AstraZeneca
  • Stuart Jacobowitz, Director of Business Development, Freemind Group LLC
  • Douglas W. Jamison, Chairman of the Board, Chief Executive Officer & Managing Director Harris + Harris Group
  • Kristen Kosofsky, Managing Director, Horizon Technology Finance LLC
  • John C. March, PhD, Associate Professor, Cornell University
  • Michael Martin, PhD, Takeda Pharmaceuticals International, Inc.
  • Christopher Morrey, PhD, Editor , BMC-series Journals, BioMed Central
  • Sanjeev Munshi, Merck
  • Stephen Nagler, Managing Director, MEDPRO Investors LLC
  • Jae Park, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center
  • John Pennent, Partner, EisenerAmper
  • William S. Podd, President & Executive Director, Landmark Angels, Inc.
  • Alexander S. Preker, President & CEO, Health Investment & Financing Corporation
  • Dennis J. Purcell, Senior Managing Director, Aisling Capital LLC
  • Ashish Raj, PhD, Associate Professor of Neuroscience, Brain Mind Research Institute, Weill Cornell Medical College
  • Jason Rando, Executive Vice President & Chief Operating Officer, Tiberend Strategic Advisors
  • Paul M. Richter, Jr, JD, Partner, Kenyon & Kenyon
  • Barbara Ryan, Managing Director, Strategic Communications Practice, FTI Consulting
  • Barbara S. Schilberg, Managing Director/CEO, BioAdvance
  • Rachel Schindler, MD, Vice President, Clinical Disease Area Expert, Neurosciences & Alzheimer’s disease, Pfizer, Inc.
  • Cecilia Schott, PharmD, Head Personalized Healthcare, Corporate Development & Ventures, AstraZeneca
  • Reginald Seeto, MD, Vice President and Head, Partnering and Strategy, MedImmune LLC
  • Evonne Sepsis, Managing Director, ECS Advisors
  • Jennifer P. Seibert, MSc. MBA, Chief Executive Officer, GAP Ventures
  • David B. Solit, MD, Geoffrey Beene Chair, Director, Center for Molecular Oncology, Memorial Sloan-Kettering Cancer Center
  • Deborah A. Somerville, Partner, Kenyon & Kenyon LLP
  • Jeremy Springhorn, PhD, Vice President, Corporate Strategy and Business Development, Alexion Pharmaceuticals, Inc.
  • Anthony Y. Sun, MD, Partner, Aisling Capital
  • Amir P. Tamiz, PhD, Program Director, National Institute of Neurological Disorders and Stroke. National Institute of Health
  • Misti Ushio, PhD, Managing Director and Executive Vice President, Harris & Harris Group, Inc.
  • Terry C. Vance, Chief Business Officer, BioMotiv
  • Gregory Verdine, PhD, Founder & Chief Executive Officer, Warp Drive Bio
  • Geoffrey von Maltzahn, PhD, New Ventures Principal, Flagship Ventures
  • Felicia Vonella, Director, Investor Relations & Corporate Communications, Acorda Therapeutics
  • Gunther Winkler, PhD, Co-Founder and Chief Executive Officer, BioMetheus
  • Peter Young, Executive-in-Residence, A. M. Pappas & Associates